141 related articles for article (PubMed ID: 30867339)
1. mTOR in cerebrovascular disease.
Van Skike CE; Galvan V
Aging (Albany NY); 2019 Mar; 11(5):1331-1332. PubMed ID: 30867339
[No Abstract] [Full Text] [Related]
2. Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer's disease and vascular cognitive impairment.
Van Skike CE; Jahrling JB; Olson AB; Sayre NL; Hussong SA; Ungvari Z; Lechleiter JD; Galvan V
Am J Physiol Heart Circ Physiol; 2018 Apr; 314(4):H693-H703. PubMed ID: 29351469
[TBL] [Abstract][Full Text] [Related]
3. mTOR drives cerebral blood flow and memory deficits in LDLR
Jahrling JB; Lin AL; DeRosa N; Hussong SA; Van Skike CE; Girotti M; Javors M; Zhao Q; Maslin LA; Asmis R; Galvan V
J Cereb Blood Flow Metab; 2018 Jan; 38(1):58-74. PubMed ID: 28511572
[TBL] [Abstract][Full Text] [Related]
4. Vascular mTOR-dependent mechanisms linking the control of aging to Alzheimer's disease.
Galvan V; Hart MJ
Biochim Biophys Acta; 2016 May; 1862(5):992-1007. PubMed ID: 26639036
[TBL] [Abstract][Full Text] [Related]
5. mTOR Attenuation with Rapamycin Reverses Neurovascular Uncoupling and Memory Deficits in Mice Modeling Alzheimer's Disease.
Van Skike CE; Hussong SA; Hernandez SF; Banh AQ; DeRosa N; Galvan V
J Neurosci; 2021 May; 41(19):4305-4320. PubMed ID: 33888602
[TBL] [Abstract][Full Text] [Related]
6. A Perfect sTORm: The Role of the Mammalian Target of Rapamycin (mTOR) in Cerebrovascular Dysfunction of Alzheimer's Disease: A Mini-Review.
Van Skike CE; Galvan V
Gerontology; 2018; 64(3):205-211. PubMed ID: 29320772
[TBL] [Abstract][Full Text] [Related]
7. Multifarious roles of mTOR signaling in cognitive aging and cerebrovascular dysfunction of Alzheimer's disease.
Uddin MS; Rahman MA; Kabir MT; Behl T; Mathew B; Perveen A; Barreto GE; Bin-Jumah MN; Abdel-Daim MM; Ashraf GM
IUBMB Life; 2020 Sep; 72(9):1843-1855. PubMed ID: 32472959
[TBL] [Abstract][Full Text] [Related]
8. Activation of mTOR modulates SREBP-2 to induce foam cell formation through increased retinoblastoma protein phosphorylation.
Ma KL; Liu J; Wang CX; Ni J; Zhang Y; Wu Y; Lv LL; Ruan XZ; Liu BC
Cardiovasc Res; 2013 Dec; 100(3):450-60. PubMed ID: 24068000
[TBL] [Abstract][Full Text] [Related]
9. mTOR: at the crossroads of aging, chaperones, and Alzheimer's disease.
Gouras GK
J Neurochem; 2013 Mar; 124(6):747-8. PubMed ID: 23278352
[No Abstract] [Full Text] [Related]
10. Cerebrovascular dysfunction links aging to neurological disease.
Van Skike CE; Galvan V
Aging (Albany NY); 2020 Jul; 12(14):13847-13848. PubMed ID: 32756010
[No Abstract] [Full Text] [Related]
11. mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging.
Van Skike CE; Lin AL; Roberts Burbank R; Halloran JJ; Hernandez SF; Cuvillier J; Soto VY; Hussong SA; Jahrling JB; Javors MA; Hart MJ; Fischer KE; Austad SN; Galvan V
Aging Cell; 2020 Jan; 19(1):e13057. PubMed ID: 31693798
[TBL] [Abstract][Full Text] [Related]
12. Folic acid delays development of atherosclerosis in low-density lipoprotein receptor-deficient mice.
Pan S; Liu H; Gao F; Luo H; Lin H; Meng L; Jiang C; Guo Y; Chi J; Guo H
J Cell Mol Med; 2018 Jun; 22(6):3183-3191. PubMed ID: 29571225
[TBL] [Abstract][Full Text] [Related]
13. The blood-brain barrier in Alzheimer's disease.
Vinters HV; Pardridge WM
Can J Neurol Sci; 1986 Nov; 13(4 Suppl):446-8. PubMed ID: 2947668
[TBL] [Abstract][Full Text] [Related]
14. Effect of everolimus on pre-existing atherosclerosis in LDL-receptor deficient mice.
Beutner F; Brendel D; Teupser D; Sass K; Baber R; Mueller M; Ceglarek U; Thiery J
Atherosclerosis; 2012 Jun; 222(2):337-43. PubMed ID: 22446027
[TBL] [Abstract][Full Text] [Related]
15. Alterations of the blood-brain barrier and glial cells in white matter lesions in cerebrovascular and Alzheimer's disease patients.
Leys D; Hénon H; Pasquier F
Stroke; 1997 Apr; 28(4):874-6. PubMed ID: 9099213
[No Abstract] [Full Text] [Related]
16. Total Flavonoids of Engelhardia roxburghiana Wall. Leaves Alleviated Foam Cells Formation through AKT/mTOR-Mediated Autophagy in the Progression of Atherosclerosis.
Wei J; Huang L; Li D; He J; Li Y; He F; Fang W; Wei G
Chem Biodivers; 2021 Sep; 18(9):e2100308. PubMed ID: 34259387
[TBL] [Abstract][Full Text] [Related]
17. Dysfunction of the mTOR pathway is a risk factor for Alzheimer's disease.
Yates SC; Zafar A; Hubbard P; Nagy S; Durant S; Bicknell R; Wilcock G; Christie S; Esiri MM; Smith AD; Nagy Z
Acta Neuropathol Commun; 2013 May; 1():3. PubMed ID: 24252508
[TBL] [Abstract][Full Text] [Related]
18. Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) Is a Novel Nutritional Therapeutic Target for Hyperlipidemia, Non-Alcoholic Fatty Liver Disease, and Atherosclerosis.
Go GW
Nutrients; 2015 Jun; 7(6):4453-64. PubMed ID: 26046396
[TBL] [Abstract][Full Text] [Related]
19. Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature.
Caccamo A; De Pinto V; Messina A; Branca C; Oddo S
J Neurosci; 2014 Jun; 34(23):7988-98. PubMed ID: 24899720
[TBL] [Abstract][Full Text] [Related]
20. Geniposide-mediated protection against amyloid deposition and behavioral impairment correlates with downregulation of mTOR signaling and enhanced autophagy in a mouse model of Alzheimer's disease.
Zhang Z; Wang X; Zhang D; Liu Y; Li L
Aging (Albany NY); 2019 Jan; 11(2):536-548. PubMed ID: 30684442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
